Pinealon at a Glance

• Pinealon is the synthetic tripeptide Glu-Asp-Arg abbreviated EDR. At roughly 418 Da it is one of the smallest compounds in general research-peptide circulation.
• It belongs to the peptide bioregulator programme associated with Vladimir Khavinson and the St Petersburg Institute of Bioregulation and Gerontology the same programme that produced Epithalon (AEDG).
• Its defining mechanistic claim is unusually strong: that short peptides of this class enter the cell nucleus, interact directly with DNA and modulate gene expression in a sequence-specific manner in effect acting as miniature transcription factors.
• Its reported biological effects concentrate on neuroprotection under oxidative and metabolic stress: increased cell viability, suppression of reactive oxygen species and reduced apoptosis in cultured neurons, and protection of rat offspring in prenatal metabolic-stress models.
• The literature is dominated by a single institute and independent replication of the core claims is essentially absent.
• The mechanistic claims outrun the independent evidence and this article says so explicitly. A tripeptide of common amino acids achieving sequence-specific DNA recognition is a major claim that the available structural chemistry does not support.
• Pinealon is not approved by the FDA, the EMA or any comparable authority. Material sold for laboratory work is research-use-only.

What Is Pinealon?

Pinealon is the synthetic tripeptide L-glutamyl-L-aspartyl-L-arginine conventionally written Glu-Asp-Arg or abbreviated EDR. The sequence is catalogued in PubChem as Glu-Asp-Arg, CID 10273502, with the molecular formula C₁₅H₂₆N₆O₈ and a molecular weight of approximately 418.4 Da.

Its chemistry is worth stating plainly, because it constrains what is plausible.

Three residues, all common, none aromatic. The molecule has no aromatic side chains, no cysteine, no methionine, no secondary structure and no possibility of a folded binding surface. It is a short, flexible, highly polar chain.

It carries both negative and positive charge. Glutamate and aspartate are acidic; arginine is strongly basic and remains protonated across the physiological range. The molecule is therefore zwitterionic with a net charge near zero at neutral pH with a guanidinium group capable of electrostatic and hydrogen-bonding interaction with phosphate backbones. That is the chemical basis of the DNA-interaction hypothesis, and it is a real property, but electrostatic affinity for the phosphate backbone is precisely the kind of interaction that is not sequence-specific.

Both termini are free. There is no N-terminal acetylation, no C-terminal amidation and no proline-rich stabilising motif, so the molecule is a straightforward substrate for aminopeptidases, carboxypeptidases and dipeptidases; in serum, tissue homogenate or any biological matrix it should be degraded within minutes.

The name is a source of confusion. “Pinealon” suggests derivation from the pineal gland, and the compound is frequently marketed alongside pineal preparations. Its relationship to the pineal gland is through the naming conventions of the bioregulator programme rather than through isolation from pineal tissue: EDR is a designed tripeptide, not a pineal extract fragment. That distinguishes it from Epithalon, which was at least derived from the amino acid composition of a real bovine pineal extract.

How Does Pinealon Work?

The Khavinson Bioregulator Framework

Pinealon cannot be understood in isolation, because its mechanistic account is not specific to it. It is one entry in a family of short peptides, AEDG (Epithalon), EDR (Pinealon), KE, AEDL, KED and others advanced by the same programme under a single unifying theory: that short peptides are endogenous regulators of gene expression. The claim is that peptides of two to four residues, generated by proteolysis of larger proteins, penetrate cells and nuclei, bind specific DNA sequences or histones, and thereby regulate transcription of particular genes, with each peptide assigned a characteristic tissue and a characteristic set of target genes.

The framework is set out across a series of reviews, including a systematic review of peptide regulation of gene expression (PMID 34834147) and an earlier account of short peptides regulating gene expression (PMID 27909961).

Two things should be said before any specific claim is assessed. The framework is internally coherent it makes predictions, and the programme has generated a large body of work testing them. And it is almost entirely the product of one institute which means the framework and its supporting evidence have not been separated by independent examination.

The Nuclear Penetration and Promoter Binding Hypothesis

This is the specific claim that carries the most weight and has the least support.

The proposition is that short peptides cross the plasma membrane and the nuclear envelope, reach chromatin, and bind DNA in a sequence-selective manner analogous to transcription factor binding. The most direct statement of it in the indexed literature is a paper arguing that the DNA double helix binds regulatory peptides similarly to transcription factors (PMID 15990728). For EDR specifically, a 2021 paper in Molecules proposed a mechanism of gene expression and protein synthesis regulation relevant to the pathogenesis of Alzheimer’s disease (PMID 33396470), and much of the supporting argument in that literature is in silico molecular docking and modelling of peptide–DNA interaction.

The status of this hypothesis should be stated as clearly as the hypothesis itself.

Sequence-specific DNA recognition in known biology requires substantially more molecular surface than a tripeptide has. Transcription factor DNA-binding domains are typically 60 to 100 residues, folded, and read bases through direct hydrogen bonds and shape complementarity in the major groove. A three-residue flexible chain has no fold to present, and its most likely DNA interaction, arginine guanidinium to phosphate backbone, is the least sequence-discriminating interaction available.

Molecular docking is not evidence of binding. Docking software generates plausible-looking poses for almost any small ligand against almost any nucleic acid target, and absent a measured binding constant, a structure or a competition assay it establishes only that a calculation was performed. There is no published crystal, NMR or cryo-EM structure of an EDR–DNA complex from an unrelated laboratory, and no independently measured affinity.

The pharmacokinetics run against the mechanism. A zwitterionic tripeptide with free termini should be hydrolysed within minutes in any biological matrix and should not cross lipid membranes readily by passive diffusion, yet the mechanism requires it to survive long enough to reach the nucleus. No published pharmacokinetic or cellular-uptake study resolves that tension, the single most important gap in the dossier, because it is a prerequisite for everything else.

Antioxidant and Anti-Apoptotic Effects

Set the gene-regulation hypothesis aside and a more modest, better-attested set of observations remains: Pinealon reduces markers of oxidative stress and cell death in cultured neurons under stress.

Khavinson and colleagues (2011, PMID 21978084) reported in Rejuvenation Research that Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes with the standard endpoints for this kind of work: viability assays, intracellular reactive oxygen species measurement, and counts of necrotic or apoptotic cells.

It is worth noting what kind of finding this is. Reduced ROS and improved viability in stressed cell culture is a common result. Many small molecules produce it, including amino acids themselves, and glutamate and aspartate are metabolic substrates whose addition to a stressed culture can plausibly alter redox handling by routes having nothing to do with gene regulation. A free-amino-acid control, equimolar Glu, Asp and Arg, unlinked, is the obvious experiment and its presence or absence in a study is the fastest way to judge how much that study establishes.

What the Mechanism Does Not Explain

The framework assigns each peptide a tissue and a gene set, but no stated rule predicts which peptide should act on which tissue. Nothing in the chemistry of Glu-Asp-Arg identifies it as neural rather than hepatic or immune. Nor does the framework explain specificity at the whole-organism level: if short peptides of common amino acids were general regulators of transcription, ordinary proteolytic turnover of dietary and endogenous protein would generate them continuously and in far larger quantities than any administered dose.

Research Evidence

Cell Culture Work

The in vitro dataset is the compound’s most substantial. It consists principally of experiments in dissociated or organotypic neuronal cultures typically rat cerebellar granule cells or cortical neurons, exposed to a stressor such as hydrogen peroxide, glutamate excitotoxicity, hypoxia or homocysteine, with Pinealon added at micromolar concentrations reported as in vitro molarity in the specific culture system used and carrying no implication for any other system, species or route.

Reported outcomes are increased viability, reduced intracellular ROS, reduced necrotic and apoptotic cell counts, and in some studies altered expression of stress-response or apoptosis-related genes. Related work from the programme has examined short peptides in fibroblast-derived induced neurons reporting protection from age-related changes (PMC11546785).

Three limitations recur: blinding of cell counts is rarely described, free-amino-acid controls are generally absent, and the concentrations used are typically far above what a rapidly hydrolysed tripeptide could plausibly sustain in vivo.

Prenatal Stress Models in Rats

The most substantive animal work comes from the Arutjunyan group in St Petersburg, working in collaboration with the Khavinson programme.

Arutjunyan, Kozina, Stvolinskiy, Bulygina, Mashkina and Khavinson (2012, PMID 22567179) reported that Pinealon protects the rat offspring from prenatal hyperhomocysteinaemia a model in which maternal hyperhomocysteinaemia is induced by dietary methionine loading during gestation. Administration of the tripeptide to pregnant rats was reported to improve offspring spatial navigation and learning and to make isolated cerebellar neurons from those offspring more resistant to oxidative stress, with reduced reactive oxygen species accumulation and fewer necrotic cells. Related work within the same programme has used prenatal hypoxia paradigms on the same logic: an intrauterine insult that impairs later cognitive performance, with the peptide tested for protection.

This is a more interesting design than the cell work, because it links a molecular readout to a behavioural one across a developmental window. Its limitations are the familiar ones: the work is from the originating network, the journal has limited reach, group sizes are small, and the maternal-administration design leaves the peptide’s route to the fetal brain, through maternal circulation, placenta and fetal blood–brain barrier, entirely unaddressed for a molecule with the pharmacokinetic profile described above.

Alzheimer’s Disease Model Work, and a Published Correction

Khavinson and colleagues reported neuroprotective effects of tripeptides described as epigenetic regulators in a mouse model of Alzheimer’s disease, in Pharmaceuticals in 2021 (PMC8227791). Pinealon appears in that work alongside other short peptides from the series, with reported effects on behavioural and histological endpoints.

Two features belong in an honest account. The framing as epigenetic regulation is a shift from the earlier direct-DNA-binding language, and the two are not the same mechanism: histone-level modulation and sequence-specific promoter binding make different predictions and require different evidence. And the paper subsequently required a published correction (PMID 39861198). Corrections are a normal part of publishing and do not by themselves invalidate a study, but in a literature where independent replication is absent they carry more weight than they otherwise would, because there is no parallel dataset to fall back on.

The Single-Institute Problem

Search the indexed literature for EDR, Pinealon, or the wider bioregulator series and the author lists overlap almost completely. Khavinson appears on the mechanistic reviews, the in vitro work, the animal work and the disease-model work: the framework, the hypotheses, the experiments and the interpretation come from one programme over roughly four decades.

That is not evidence of error. Productive research programmes concentrate expertise, and the Russian peptide-regulation tradition produced genuinely novel ideas. But independent replication is the mechanism by which science removes group-specific methodological artefacts and for Pinealon that mechanism has essentially not operated. The contrast with its sister compound is instructive: Epithalon’s central in vitro claim finally received an independent examination from an unrelated laboratory in 2025. Pinealon has had no equivalent.

What Remains Unknown

Cellular uptake and nuclear entry are undemonstrated by any independent method, the load-bearing step in the proposed mechanism. Pharmacokinetics are uncharacterised: no published study establishes plasma half-life, tissue distribution or brain exposure for EDR in any species. No target has been identified with measured affinity by an independent group.

No registered clinical trial exists. A search of ClinicalTrials.gov does not return a registered interventional trial of Pinealon, and there is no randomised, blinded human data of any kind. And whether the effects require the intact tripeptide is untested: without free-amino-acid controls, the possibility that observed effects reflect amino acid supply rather than peptide-specific signalling remains open.

Comparison: Pinealon, Epithalon and Semax

These three are sold together as “short Russian research peptides” and routinely treated as members of a class. They are not: their mechanistic hypotheses are unrelated and their evidence bases differ in quality, which is the axis worth comparing.

Epithalon is Pinealon’s closest relative and the better-documented of the two. It shares the same programme, the same proposed gene-regulatory mechanism and the same provenance problem, but has two things Pinealon does not: a derivation from a real tissue extract, and an independent in vitro replication of its central telomere claim from an unrelated laboratory. An independent 2025 review nonetheless noted that despite the volume of biological research on the peptide, physico-chemical and structural investigation of it remains quite limited (PMID 40141333), a criticism that applies to Pinealon with greater force. Catalogues list Epithalon as a separate research compound.

Semax sits in a different evidential category despite sharing shelf space. Its pharmacology is conventional: Dolotov and colleagues (2006, PMID 16996037) reported that it regulates BDNF and trkB expression in the rat hippocampus with companion work reporting specific binding in brain tissue. That is a nameable target family and a measurable downstream readout, a materially stronger mechanistic position than a docking figure, even though Semax’s own clinical literature is also concentrated in one national tradition. Semax appears in the same catalogues.

For a laboratory holding all three, the practical conclusion is that they should not be treated as interchangeable members of a class. On mechanism and on evidence they are three different propositions, and Pinealon is the weakest of the three.

Handling and Reconstitution of Lyophilised Pinealon

At three residues and roughly 418 Da, Pinealon is among the simplest molecules in research-peptide handling, with one important vulnerability.

Solubility is never limiting. Two acidic residues and an arginine make the molecule strongly polar, and it dissolves freely in aqueous buffer with no organic co-solvent required.

There are no oxidation-prone residues no cysteine, methionine, tryptophan or aromatic side chains at all, which removes the degradation routes that dominate stability discussions for most peptides. The realistic degradation chemistry is deamidation and backbone hydrolysis at the acidic residues accelerated by temperature extremes and by pH away from neutral. Lyophilised material kept cold and dry is stable.

Enzymatic hydrolysis is the real risk, and it is severe. A three-residue peptide with free termini is an ideal substrate for aminopeptidases, carboxypeptidases and dipeptidases. In any preparation containing serum, tissue homogenate, cell lysate or microbial contamination the peptide degrades rapidly, the most likely single explanation for irreproducible results in cell work with this compound. Serum-free conditions, protease inhibitors where compatible with the assay, and short exposure windows all materially change what the experiment measures, which is why any credible in vitro result should state the medium composition.

Practical reconstitution follows the standard sequence: equilibrate the vial to room temperature before opening, disinfect the septum with 70% isopropyl alcohol and let it dry, introduce the diluent slowly down the inner wall of the vial rather than onto the cake, and swirl or roll gently rather than shaking.

Where a vial will be entered repeatedly, a preserved monographed diluent is the conventional laboratory choice, and the bacteriostatic water listed alongside research compounds at NextGenPeps, or an equivalent Bacteriostatic Water for Injection, USP product, is what most protocols specify. Two caveats belong in the record. The benzyl alcohol preservative is not inert toward peptides, the formulation literature documents preservative-promoted unfolding and aggregation across model peptides, so single-entry analytical preparations are better served by unpreserved sterile water. And it is contraindicated in neonatal use because of benzyl alcohol toxicity, a restriction that belongs in handling notes even where no clinical use is contemplated.

Store reconstituted solution at 2–8 °C, buffer near neutral pH where the system allows, aliquot at the point of reconstitution rather than freeze–thawing repeatedly, and log the diluent lot alongside the peptide lot.

Is Pinealon FDA Approved?

No. Pinealon is not approved by the FDA, the EMA, the MHRA or any comparable regulatory authority, for any indication, in any species. There is no marketing authorisation, no approved labelling and no approved route of administration.

Its regulatory position is worth reporting accurately. Several Khavinson-programme preparations have been marketed within Russia and neighbouring markets as pharmaceuticals or supplements under those jurisdictions’ own frameworks, and secondary coverage frequently extends that status to Pinealon by association. Whatever the position in any individual market, none of it constitutes approval by a Western regulator and none of it is transferable: registration in one jurisdiction under a historical framework says nothing about status under FDA or EMA review, neither of which has evaluated this compound.

Pinealon is likewise not a lawful dietary supplement ingredient in the United States. A synthetic tripeptide of this kind does not qualify as a dietary ingredient, and marketing it for human consumption places it outside both the drug and the supplement frameworks.

For context on how the agency treats research peptides more generally, the FDA maintains a list of certain bulk drug substances for use in compounding that may present significant safety risks. Pinealon does not appear on it, and absence is not permission, the list governs pharmacy compounding, not research use, and says nothing about a substance that was never nominated.

The practical consequence is the usual one. Material sold for laboratory work is research-use-only no regulatory body has assessed the identity, purity or safety of any research-grade lot, and supplier documentation carries the entire evidentiary burden.

Where to Source Research-Grade Pinealon

A tripeptide is trivial to synthesise, which is precisely why the quality range in this market is wide: the barrier to producing material is low, and the barrier to producing documented material is where suppliers separate. A defensible purchase record contains:

• A lot-matched certificate of analysis tied to the specific lot shipped rather than to a representative batch.
• Third-party HPLC purity data with a named laboratory, a stated method and a test date. The impurities that matter are deletion sequences which for a three-residue peptide means a dipeptide, incompletely deprotected glutamate or aspartate side chains and deamidation products. A short polar peptide also runs early on standard reverse-phase gradients, near the injection front, which makes method detail more important here than for a long peptide.
• Mass spectrometry confirming identity with an observed mass consistent with the expected 418.4 Da. A deletion product of a tripeptide is a dipeptide, which may look acceptable on a coarse chromatogram while being a different compound.
• Sequence confirmation, not merely composition. Glu-Asp-Arg and Asp-Glu-Arg are distinct compounds with identical molecular formulae and identical masses and PubChem lists them separately. Mass spectrometry alone cannot distinguish them.
• Declared net peptide content distinct from gross vial fill weight. For a 418 Da peptide the counterion and residual-water fraction is proportionally large, so a vial labelled by fill weight overstates peptide mass substantially.
• Residual trifluoroacetate data where available, since TFA is cytotoxic at low concentrations in cell work, directly relevant where the readout is viability or ROS.
• Cold, dry storage and appropriate shipping and explicit research-use-only labelling with no suggested protocol, dosing guidance or human-use framing anywhere in the listing.

Red flags here are more often editorial than analytical. A listing that presents direct gene regulation as an established mechanism describes the compound as an epigenetic or anti-ageing therapy, or presents rodent cognitive findings as though they applied to humans has overstated a literature whose central claim has no independent structural support. A certificate with no named laboratory, test date or lot reference is decoration, and purity claims of “99%+” with no chromatogram or method are not data.

A catalogue that lists Pinealon as a research compound can be assessed against exactly these criteria: lot-matched third-party analysis with a resolved chromatogram, identity confirmed by mass spectrometry, sequence confirmation distinguishing EDR from its isomers, declared net peptide content, residual solvent figures, and research-use-only labelling with no protocol content attached. The same checklist applies to any supplier.

Frequently Asked Questions

Is Pinealon the same thing as EDR?

Yes. EDR is the single-letter abbreviation for the tripeptide Glu-Asp-Arg, and Pinealon is the name given to it within the Khavinson bioregulator series. Both terms appear in the indexed literature, and searching only one will miss part of it. “EDR peptide” is the more reliable term for recent publications.

Does Pinealon come from the pineal gland?

No, and the name is misleading. It is a designed synthetic tripeptide within a programme whose naming conventions reference tissues. Unlike Epithalon, which was synthesised on the basis of the amino acid composition of a real bovine pineal extract, EDR has no established derivation from pineal tissue.

Do short peptides really regulate gene expression by binding DNA?

That is the hypothesis, and it is not established. Its support consists of in silico docking and modelling plus biological observations from the programme that proposes it. There is no published independent structure of a peptide–DNA complex and no independently measured binding affinity. Sequence-specific DNA recognition in known biology requires far more molecular surface than a tripeptide provides, and the interaction most available to this molecule, arginine to phosphate backbone, is not sequence-discriminating.

What is the strongest evidence for Pinealon?

The cell-culture work reporting increased viability and reduced reactive oxygen species under oxidative stress, and the 2012 rat study reporting protection of offspring from prenatal hyperhomocysteinaemia with improved spatial learning and more stress-resistant cerebellar neurons. Both come from the originating research network, and neither has been independently replicated.

Why does the single-institute issue matter so much here?

Because almost the entire dossier, framework, mechanism, in vitro work, animal work and interpretation, comes from one programme. Independent replication is how science removes group-specific methodological artefacts, and for Pinealon that process has essentially not occurred.

Has Pinealon been tested in humans?

Not in any registered, randomised, blinded trial. A registry search does not return a registered interventional study of Pinealon, and there is no controlled human dataset for any claimed effect.

The Bottom Line

Pinealon is a case where the mechanistic claim and the independent evidence are further apart than for almost anything else in the research-peptide catalogue and being specific about where the gap sits is more useful than either endorsing or dismissing it.

What is reasonably supported: the molecule exists as a defined tripeptide of known composition and mass, and there is a body of reported work, consistent within itself, describing increased cell viability, reduced reactive oxygen species and reduced cell death in stressed neuronal cultures alongside a rat prenatal-stress study reporting behavioural and cellular protection in offspring.

What is not supported: the mechanism it is sold on. Nuclear penetration is undemonstrated. Sequence-specific DNA binding has no independent structural or affinity data resting substantially on docking calculations. The pharmacokinetic problem is untouched a zwitterionic tripeptide with free termini should be cleared in minutes and should not readily cross membranes, yet the mechanism requires it to reach chromatin. No free-amino-acid control is routinely reported, leaving open the plainest alternative explanation for the culture findings. And no independent laboratory has replicated any core claim in any model.

There is also a shift in framing worth noticing. The earlier literature describes direct sequence-specific DNA binding; more recent work describes epigenetic regulation. These are different mechanisms with different predictions, and moving between them without resolving the first weakens rather than strengthens the account.

The honest assessment is that the mechanistic claims outrun the independent evidence by a wide margin. Pinealon is a cheap, stable, well-defined tripeptide and a reasonable tool for cell-culture oxidative-stress work by a laboratory that includes the controls the existing literature omits. It is not an established neuroprotective agent, it is not a demonstrated regulator of gene expression, and the literature does not support describing it as either.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

Pinealon, EDR, Epithalon, Semax and all other compounds discussed in this article are intended for laboratory research use only. Pinealon is not approved by the U.S. Food and Drug Administration, the European Medicines Agency or any comparable authority for the diagnosis, treatment, cure or prevention of any disease, in any species, and is not an approved dietary supplement ingredient in the United States. Historical registration or marketing of related preparations in other jurisdictions confers no status under FDA or EMA review.

Nothing in this article is medical, veterinary or pharmaceutical advice, and nothing in it constitutes a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind. Peptides described here are not for human or veterinary use. Concentrations and doses quoted from the literature are reported in the terms the original investigators used for the specific in vitro system or animal model studied, and are not recommendations or equivalents for any other species or route. Descriptions of published findings, including claims of gene-expression regulation, neuroprotection or cognitive effects, are summaries of what the cited literature reports, not endorsements. Readers with clinical questions should consult a qualified healthcare professional. Bacteriostatic Water for Injection, USP contains benzyl alcohol and is contraindicated in neonates. Readers are responsible for compliance with all applicable laws, institutional review and animal ethics requirements, anti-doping regulations and biosafety rules in their jurisdiction.

Related posts:

Visualization in the Pediatric Patient Nerve Monitoring Factors in a Standard Work Protocol for Adult Deformity Surgery Medical Complications Peptides for Anxiety: Research, Potential Mechanisms, and What to Know

Stay updated, free articles. Join our Telegram channel

Join